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Abstract: Gastrointestinal stromal tumors (GISTs), the most common sarcoma of the GI tract, 
have unique kinase mutations that serve as targets for medical therapy. This article reviews the 
data supporting the use of the tyrosine kinase inhibitor (TKI) imatinib in GIST patients, and how 
this treatment should be combined with surgical resection (when possible) to optimize patient 
outcomes. Although surgical resection remains the mainstay of treatment for these tumors, 
patients with resected GISTs have high relapse rates that can be reduced by 1 year of adjuvant 
imatinib. Data also support the use of imatinib for patients with recurrent or unresectable GIST. 
In these patients the drug should be continued until progression, intolerance, or the patients are 
rendered resectable. Patients with advanced GIST who are successfully resected after imatinib 
treatment should be placed back on imatinib postoperatively. Patients who develop generalized 
progression (progression at 2 or more sites) on imatinib should move to other treatments, such 
as newer TKIs or other targeted approaches currently under study. Genotyping of the tumor 
should be considered in all pediatric GISTs and high risk adult GISTs, especially if there is 
progression on imatinib. Quality of life and the cost/benefit of new therapies are important 
issues for further study in patients with GIST.
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Background: GI stromal tumors and tyrosine  
kinase inhibitors
Ramon y Cajal, a Spanish neuroanatomist and neurophysiologist, is credited with 
describing interstitial cells in Auerbach’s plexus which have since been found to have 
both neural and stromal features by electron microscopy (EM). Now known as the 
Interstitial Cells of Cajal (ICC), these cells are thought to give rise to gastrointestinal 
stromal tumors (GISTs), either directly, or, alternatively, GIST and ICC may 
arise from a common mesenchymal stem cell. Like the ICC, GISTs have a classic 
immunohistochemical (IHC) staining pattern (positive for CD34, S-100, DES, keratin, 
negative for desmin), and, also like the ICC, GIST cells strongly express two kinases, 
c-kit and platelet-derived growth factor receptor (PDGF-R). In the case of GIST, 95% 
express kit and approximately 7% express PDGF-R, usually in mutated forms.1
A skilled and meticulous medical illustrator, Cajal was awarded the 1913 Nobel 
Prize (which he shared with Camillo Golgi) for his work.
Until the unique EM and IHC features of ICC and GIST were elucidated, GISTs 
were previously misclassified as leiomyosarcomas or other spindle cell cancers. In 
fact, GISTs are very different pathologically and clinically.2 Importantly, GISTs are 
typically resistant to standard sarcoma adjuvant chemotherapy, with response rates OncoTargets and Therapy 2009:2 152
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(RRs) of ∼5%, and no impact on survival. Similarly, radiation 
therapy (RT) offers mostly morbidity due in part to the fact 
that the intrabdominal location of these tumors limits its use; 
RT may have some role for rectal GISTS.
Rather, as outlined in this review, the high kinase 
expression in these tumors has allowed for treatment of 
these tumors with tyrosine kinase inhibitors (TKIs),3 which, 
when selectively combined with resection, has led to both a 
significant improvement in outcomes for this tumor and an 
explosive growth in our understanding of targeted therapy 
of solid tumors.
Resection of primary GISTs:  
pre-operative considerations
GIST may occur anywhere along the GI tract or elsewhere 
in the abdomen or retroperitoneum. Data from our and 
other institutions indicate that approximately 50% of 
primary GISTs are located in the stomach, 25% in the small 
bowel, and the rest are distributed in the colon, rectum, and 
esophagus.4
Some GISTs are found incidentally on imaging studies 
such as CT or endoscopic ultrasound (EUS) or in biopsies 
done for other reasons. Indeed, the management of these 
“microGISTs” is controversial. Tumors measuring 1 cm, 
commonly located in the stomach, have been found in 22.5% 
of autopsies of German adults older than 50,5 and in 35% of 
Japanese gastrectomy specimens removed for other reasons.6 
These small gastric GISTs are generally less aggressive than 
distal or larger tumors, and thus incidental gastric GISTs 
(usually found on endoscopy) can be followed with serial 
endoscopy and imaging as long as they remain asymptomatic. 
The management of incidental GISTs measuring 1 to 2 cm in 
size is more controversial. The mitotic rate of these tumors 
cannot be determined by fine needle aspiration, and therefore 
most surgeons would recommend resection, especially if it 
would involve minimal potential morbidity.
While all GISTs should be considered potentially 
malignant, nongastric GISTs are never considered “benign”, 
and therefore most would favor resection of these lesions 
irrespective of  size.7 Regardless, most GISTS are discovered on 
work-up for GI symptoms, and therefore are typically 2 cm 
and/or symptomatic at the time of discovery. These lesions 
clearly require therapy.
The 2007 National Comprehensive Center Network 
(NCCN) GIST Guidelines state that the first step in the 
management of a potentially respectable GIST is to determine 
resectability with tests such as computed tomography (CT) 
and/or magnetic resonance imaging (MRI), chest imaging, 
endoscopic ultrasound (EUS), and endoscopy. We favor 
triple phase (porto-venous, early arterial, and late arterial) 
CT scanning because it best elucidates and rules out liver 
metastases, the most frequent site of metastases. Fluorode-
oxyglucose-positron emission tomography (FDG-PET) is an 
excellent functional test that can be helpful in demonstrating 
tumor response to imatinib, but its role in determining resect-
ability of primary GISTS is limited and it is usually not indi-
cated. Importantly, the NCCN guidelines stress the role of a 
multidisciplinary GI program in assessing possible resection 
for primary GIST. If metastatic disease is ruled out by these 
tests preoperative biopsy of suspected GISTs is usually not 
indicated; the NCCN recommends biopsy only if the tumor 
is unresectable, if the diagnosis in doubt, or if neoadjuvant 
therapy is planned.8 If a biopsy is done EUS is usually the 
best method if the tumor is assessable endoscpically.3
Resectable GISTs should be resected  –  surgery remains the 
principal and only potentially curative therapy for localized, 
resectable primary GIST.7 After successful resection, the 
2007 NCCN guidelines recommended postoperative imatinib 
if the surgeon removed all gross disease but the operative 
specimen reveals positive microscopic margins (R1 resection) 
or if gross disease was left behind (R2 resection): observation 
was recommended if an R0 resection (negative microscopic 
margins) was achieved.8 With the recent (December 2008) 
approval by the FDA for imatinib as adjuvant therapy for 
all GISTs, the issues have become somewhat more complex 
and will be discussed at the end of this review in light of 
the information that follows regarding the available data 
to date.
Conduct and importance of surgical 
resection for primary GISTs
Once in the operating room with a patient with an apparently 
resectable GIST, the surgeon should perform complete 
gross resection of the tumor with its pseudocapsule, using a 
“no-touch technique” as much as possible. This often requires 
segmental resection rather than peritumoral resection in 
order to achieve the best margins, within the limits of any 
retroperitoneal/intraperitoneal sarcoma resection (ie, margins 
are sometimes limited by adherence of the tumor to major 
vascular structures or nerves). Optimal resection is often 
assisted by the fact that like other sarcomas, GISTS are 
“pushers” rather than “invaders” and can often be lifted off 
surrounding organs; even lesions that appeared to be invading 
adjacent structures on preoperative scans are often found to 
be respectable at operation. That is, preoperative imaging 
can sometimes underestimate the resectability of tumors. OncoTargets and Therapy 2009:2 153
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Conversely, images may have missed small tumor implants 
that may render the tumor unresectable. The surgeon should 
look for such metastases by examining liver and peritoneal 
surfaces carefully and resecting them whenever possible.3,7
Adult GISTs do behave like other sarcomas in that 
they almost never spread to nodes; therefore routine lymph 
node dissection is not required. Similarly, extra-abdominal 
metastases and ascites are rare, facts that also assist with 
surgical resection. As alluded to above, it is essential to avoid 
tumor rupture and bleeding; GISTs are fragile tumors, and 
such events promote tumor dissemination and recurrence. 
Thus, the conduct of the resection of primary GISTs is critical 
to determining patient outcomes.
Several special issues regarding GIST resection deserve 
mention. First, it is unclear whether the surgeon should 
immediately return the patient to the operating room for a 
re-operation if the final microscopic margins are positive 
(R1 resection) when the surgeon expected an R0 report. 
This appears to vary by center, but is clearly also dependent 
on the findings at operation, patient factors, and surgeon 
and patient preference. There are no data that directly 
address this issue, although many centers now recommend 
starting imatinib instead of reoperation, with clinical 
follow-up. Secondly, esophageal GISTs may require either 
esophagectomy9 or enucleation (segmental resection is not 
an option in the esophagus). Which of these very different 
operative approaches is chosen depends on tumor, patient, 
and institutional factors.3 Thirdly, because half of all GISTS 
occur in the stomach, the surgeon frequently needs to decide 
on the extent of gastric resection. Most commonly, this can 
be segmental, with major gastrectomies reserved for GE 
junction or pylorus tumors.10
Finally, the use of laparoscopy deserves special 
mention. Although the 2004 NCCN guidelines listed GIST 
as a contraindication to laparoscopic resection, our and 
other institutions have been resecting GISTs safely using 
laparoscopic or laparoscopic-assisted techniques for some 
time. In 2006 Novitsky et al reported on 50 selected cases 
of primary GIST resected laparoscopically using careful 
techniques, including the use of specimen extraction bags and 
intra-operative ultrasound/endoscopy. Forty-seven patients 
had local resections and 3 had segmental resection. The mean 
operative time and average blood loss were very favorable 
(135 min and 85 mL, respectively). At 36 months average 
follow-up, 92% of patients remained free of disease, and 4 
had recurred, all with liver metastases (ie, recurrences were 
nature of disease and not local recurrences).11 This and other 
reports3,12,13 emphasized that, as with any laparoscopic cancer 
resection, laparoscopic resection of GIST is safe as long as 
the surgeon adheres to oncologic principles, especially by 
avoiding direct instrumentation of tumor. Based on such 
reports, the 2007 NCCN guidelines listed laparoscopic 
resection as an option for the treatment of primary GIST 
tumors.8
The complete resection of a primary GIST is an important 
prognostic marker. The surgeon’s goal should always be an 
R0 resection, as complete resection of GIST remains the 
best treatment even in the era of imatinib.3 Many tumors can 
be completely resected at presentation. After R0 resection, 
the most important prognostic factors are tumor factors, 
and include tumor size (2 cm, vs 2 to 5 cm, vs 5 to 10 
cm, vs 10 cm), location (gastric best, small bowel worst), 
and tumor mitotic rate (5, vs 5 to 10, vs 10 mitoses 
[M]/50 high powered fields [hpf]).14,15 Using these criteria, 
certain subgroups of GISTs (eg, larger tumors with higher 
numbers of mitoses) can be considered as “high risk”, 
although-as will be stressed in the sections that follow-the 
definition of “high risk” can vary in the literature, among 
various institutions, and between different clinical trials. 
For example, at our institution the definition of “high risk” 
GISTs actually depends on the tumor site, which takes into 
account the importance of tumor location.4 Specifically, we 
define “high risk” for gastric GISTS as tumors 10 cm and 
having 5 M/50 hpf, and for GISTS distal to the stomach as 
those that are 5 cm and having at least 5 M/50 hpf.
Resected GIST: rationale  
for adjuvant imatinib
While GISTs are usually treated up front with resection, R0 
resection, as noted above, is clearly not the only predictor of 
patient outcome. Resected GISTs can have high recurrence 
rates, and prior to the availability of imatinib GIST patients 
had particularly high failure rates. Tumors 10 cm in size 
were associated with 5-year disease-free survival (DFS) of 
only 20% and median times to progression (TTP) of 7 months 
to 2 years. Only 10% of patients remained disease-free after 
extended follow-up.16 Given this high recurrence rate and 
the existence of an effective oral drug with a low toxicity 
profile which targets a tyrosine kinase (TK) expressed in over 
95% of tumors, it was only natural that clinical investigators 
turned research endeavors towards combining resection with 
systemic approaches using Imatinib.
Imatinib (Gleevec®; Novartis) is a TKI which inhibits 
the Philadelphia chromosomal Bcr-Abl and the TK c-kit. It 
is also thought to induce apoptosis (see below). The most 
encouraging rationale for the use of this inhibitor in GIST OncoTargets and Therapy 2009:2 154
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were data from the Multicenter (“Pivotal”) trial,17 Sarcoma 
Intergroup Trial,18 The European Organization for Research 
and Treatment of Cancer (EORTC)-Italian Sarcoma Group-
Australasian Gastrointestinal Trials Group,19 and other 
trials3 of imatinib in patients with advanced (unresectable 
and metastatic) GIST. These studies demonstrated clinical 
benefit in over 80% of patients, with survival dramatically 
better than historical controls from the Southwest Oncology 
Group (SWOG) 8616 and 9627 trials.16
Pharmacology of imatinib
Imatinib, a 2-phenylaminopyrimidine derivative, is a specific 
inhibitor of a number of TK enzymes. It binds to the TK 
active site, leading to a decrease in kinase activity (Figure 1). 
Imatinib is specific for the TK domain in abl (the Abelson 
proto-oncogene), c-kit and PDGF-R. Imatinib is rapidly 
absorbed orally and is highly bioavailable: 98% of an oral 
dose reaches the bloodstream. Metabolism of imatinib 
occurs in the liver and is mediated by several isozymes of 
the cytochrome P450 system, including CYP3A4 and, to a 
lesser extent, CYP1A2, CYP2D6, CYP2C9, and CYP2C19. 
The main metabolite, N-demethylated piperazine derivative, 
is also active. The major routes of elimination are billiary 
and enteral; only a small portion of the drug is excreted in 
the urine. Most of imatinib is eliminated as metabolites: only 
25% is eliminated unchanged. The half-lives of imatinib and 
its main metabolite are 18 and 40 hours, respectively.20
Resected GIST: adjuvant  
trials/efficacy studies
Based on the above mentioned encouraging data on imatinib 
in advanced GIST, the American College of Surgeons 
Oncology Group (ACoSOG) embarked on 2 adjuvant trials of 
imatinib after resection of primary GIST – a nonrandomized 
phase II administration of imatinib to patients with high 
risk GIST (ACoSOG Z9000), and a placebo-controlled, 
randomized study of imatinib for more intermediate-risk 
patients (ACoSOG Z9001).7
The primary objective of the Z9000 trial was overall 
survival (OS) after administration of 400 mg/day for 1 year 
of the drug to patients after resection of high risk GIST; the 
secondary objectives were 2- and 5-year recurrence and 
toxicity. To be included in the trial patients needed to be 
imatinib-naïve, have tumors that were c-KIT positive, received 
no prior adjuvant therapy, and undergo at least an R1 resection 
with no residual disease on post-operative imaging. “High 
risk” for this trial was defined as any of the following: tumors 
at least 10 cm in greatest dimension, the presence of tumor 
rupture before or during operation, intraperitoneal hemorrhage, 
or the finding at operation of multifocal intraperitoneal tumors 
(all resected); ie, number of mitoses was not included in the 
definition of high risk.
The 4-year results of  this trial were presented by DeMatteo 
et al in 2008. Among the 107 eligible patients, imatinib was 
started at a median of  59 (range 25 to 84) days after operation. 
Patients had a median age of 58 years (range 19 to 79) and 
a median tumor size of 13 cm (range 3 to 42). Fifty percent 
of the tumors were gastric and 42% were small intestine. 
Imatinib therapy was well tolerated (previously reported 
in 2005)21.  At a the median follow-up of 4 years the 
1-, 2-, and 3-year OS were 99%, 97%, and 97%, respectively, 
and the 1-, 2-, and 3-year relapse-free survivals (RFS) were 
94%, 73%, and 61%, respectively. The authors concluded 
that imatinib 400 mg for 1 year after resection of high-
risk primary GIST prolonged RFS and OS compared with 
historical controls.22
The primary objective of the Z9001 trial was to determine 
the OS of patients with GIST treated with imatinib (again, 
400 mg/day for 1 year) in an adjuvant setting relative to placebo. 
The secondary objectives were RFS and safety/efficacy 
in an adjuvant setting. This trial included all patients with 
GISTS  3 cm, resected within 70 days prior to registration, 
who had kit-positive tumors, were imatinib-naïve, and had no 
prior adjuvant therapy.
The preliminary results of this trial were presented by 
DeMatteo et al in 2007. At a median follow-up of 1.2 years, the 
1-year RFS among the 708 completely resected patients was 
97% for the imatinib arm, and 83% for placebo. This difference 
reached statistical significance for tumors 6 cm. No effect on 
OS has yet been seen; 10-year survival follow-up is ongoing.23
Based on these and other trials, imatinib was FDA 
approved in December 2008 for the adjuvant treatment of all 
bcr-abl bcr-abl
bcr-abl
Kinase domain
Substrate, eg,
GRB-2, SHC
Substrate cannot
enter kinase site
Imatinib competitively binds
to site and inhibits protein
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cannot proliferate
Substrate activated
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Figure 1 Mechanism of action of imatinib (source: http:\\wikipedia/imatnib [accessed 
March 2, 2009]).OncoTargets and Therapy 2009:2 155
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resected primary GISTs. Ongoing trials continue to address 
the question of adjuvant imatinib, including a study from the 
EORTC (for GIST  3 cm, randomizing 2 years of imatinib 
vs placebo), and a trial from the Scandinavian Sarcoma Group 
(randomizing between 12 vs 36 months of treatment in high 
risk GIST patients).7
Overtreatment of GIST patients with adjuvant imatinib, 
an expensive drug with known toxicity, is an obvious concern 
for a number of reasons. First, as noted above, the random-
ized trials leading to FDA approval included only those 
GISTs  3 cm, with a statistically significant improvement 
in RFS only for tumors 6 cm. Secondly, the data as yet 
show no improvement in OS. Thirdly, the ACoSOG studies 
were not stratified by mitotic rate, now known to be a key 
prognostic factor. Finally, small, good prognosis GISTS may 
be cured with surgical resection alone-although at present 
there are no definite markers to identify these patients.
Safety and tolerability of imatinib  
in GIST patients
Common reactions reported with imatinib include fever, 
headaches, fluid retention (peripheral and periorbital 
edema), nausea and vomiting, dyspepsia, muscle cramps 
and pain, arthralgias, diarrhea, hemorrhage and anemia, 
neutropenia, upper respiratory infections, and elevated liver 
transaminases and bilirubin. Patients receiving imatinib 
should be monitored with liver function tests and consider-
ation should be given for baseline troponins and electrocardio-
gram if they are being treated for hematologic disorders, and 
thyroid function tests if they have had a thyroidectomy.
Early results from the ACoSOG included a 2005 report 
by DeMatteo et al regarding the safety and tolerability of 
imatinib in patients with GIST; given orally 400 mg/daily 
for 1 year, the drug was well tolerated. No grade 4 or 5 
toxicity was seen. Nineteen (17%) patients had grade 3 
toxicity, consisting of neutropenia (2%), dermatitis (2%), 
and increased ALT (2%). The most frequent toxicities of any 
grade included edema (55%), fatigue (43%), nausea (42%), 
diarrhea (42%), and dermatitis (27%). Eighty-seven (82%) 
patients completed the 1 year of imatinib, and 72 (68%) 
tolerated full dose without a dose reduction.21
Rare but serious reactions reported with imatinib include 
liver failure (ascites, anasarca, hepatotoxicity), left ventricular 
dysfunction (pulmonary edema, pleural effusions, congestive 
heart failure [CHF], pericardial effusions), thrombocytopenia 
and bleeding (GI hemorrhage, anemia), neutropenia, exfolia-
tive dermatitis, hypokalemia, hypothyroidism, and – very 
rarely – Stevens-Johnson syndrome and erythema multiforme. 
As with any TKI, imatinib should be used with caution in 
patients with hypersensitivity to TKIs, cardiac risk factors, 
or impaired liver function, as the drug is extensively metabo-
lized in the liver; only 12% is renally excreted.20 Patients 
should avoid pregnancy and breast feeding.
Rarely, patients with advanced GIST on TKI therapy may 
develop complications such as intraluminal or intraperitoneal 
hemorrhage, rupture, abscess, fistula, or obstruction, 
necessitating emergency operation. All 3 operative deaths 
in one series occurred in patients undergoing emergency 
surgery.24 Accordingly, pre-emptive operation should be 
considered in patients with evidence of fistulization, ongoing 
necrosis, or limited hemorrhage.7
Advanced GIST: rationale  
for neoadjuvant and palliative 
imatinib
As mentioned above, imatinib was first tested in patients with 
advanced GIST. The rationale for this testing was clear: 95% 
of GIST express mutated c-KIT, and operative therapy alone 
for advanced GIST, as mentioned above, would be expected 
to fail in the majority of cases. Also as mentioned previously, 
subsequent trials, especially the Pivotal Trial, demonstrated 
that over 80% of patients with advanced GIST derive some 
clinical benefit.17–19
Given these findings, imatinib has been applied to 
patients with operable GIST in one neoadjuvant trial,25 and 
to inoperable GIST in the hope of rendering the disease 
operable.3,7,26 This combined medical-surgical approach 
in advanced GIST is based on the facts that there are 
few complete responses with imatinib alone in advanced 
disease, that responding lesions when biopsied/resected 
usually contain viable cells, data from other tumor types that 
cytoreduction may improve surgical outcomes, the general 
idea that recurrent GIST behaves like metastatic disease and 
therefore may best be treated with a multimodal approach, 
and that imatinib given preoperatively has the potential to 
increase resectability or reduce the extent of surgery.7
Data from the Pivotal Trial demonstrated that the median 
time to overall response in patients with advanced GIST 
treated with imatinib was 13 weeks, and that 80% (of the 
80% of patients who responded) did so within 6 months of 
therapy.17 Conversely, it is rare to see incremental tumor 
shrinkage after 9 months, and the median time to progression 
on imatinib is approximately 2 years.27 Accordingly, centers 
using imatinib for advanced GIST in the hope of rendering 
patients resectable generally follow patients (who are 
responding) out on at least 6 months of therapy before OncoTargets and Therapy 2009:2 156
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considering surgical exploration, but usually operate before 
24 months.7
Imatinib and surgery for advanced 
GIST: outcomes
The Radiation Therapy Oncology Group (RTOG) 0132 trial 
was a phase II study of neoadjuvant/adjuvant imatinib given 
for advanced primary and metastatic/recurrent operable GIST. 
Imatinib was given to 52 patients at 600 mg/day; 30 patients 
had primary GIST (group A) and 22 had recurrent/metastatic 
GIST (group B). All were felt to be operable; 7% of group 
A and 4.5% of group B had partial preoperative responses to 
imatinib, while 4.5% of group B progressed. The remainder 
had stable disease. Two-year PFS and OS were 83% and 93%, 
for Group A, and 77% and 91% for Group B, respectively. 
Complications of operation and toxicity of imatinib were 
judged to be minimal. Accordingly, the authors concluded 
that neoadjuvant imatinib is feasible, and not associated with 
notable postoperative complications.25
One of the issues with this trial is that patients were 
evaluated for radiographic response to imatinib using the 
Response Evaluation in Solid Tumors (RECIST) criteria. 
These criteria, which are based on size changes on anatomic 
imaging, can under call response of GIST tumors to imatinib 
because 1) response, especially early on, can consist mostly 
of “dynamic” changes in the tumor (eg, decreased FDG-PET 
uptake and decreased tumor density on contrast-enhanced 
CT [CE-CT] scans), and 2) some responding GIST tumors 
may actually swell, a situation which may be labeled as 
progression by RECIST criteria if the increase in size of the 
sum of the greatest diameters of the tumors exceeds 20%. 
Accordingly, many oncologists favor the newer Choi Criteria 
for radiographic evaluation of GIST response to therapy, 
which include a dynamic measure of response (a 15% 
decrease in tumor density on CE-CT).28
The data on combined medical-surgical therapy for 
advanced and inoperable (or “possibly operable”) GIST at 
present consists of small series; these studies report response 
rates a high as 76%, similar to the findings of the Pivotal 
Trial. Approximately 25% of unresectable primary and 
recurrent/metastatic lesions convert to resectable, and long 
term disease control has been documented.7,27,30 The timing 
of resection can be tricky; surgeons generally want to wait 
until the patient has had a maximum response to TKI therapy 
but this cannot always be known in foresight-the minimum 
6 months of TKI therapy is usually given as discussed in the 
previous section. After resection most surgeons resume TKI 
post op; in the French Sarcoma Group and RTOG S-0132 
studies patients recurred quickly if the imatinib was stopped 
postoperatively.7,25,31
Six studies to date have provided surgical outcomes data 
for patients with advanced GIST going to operation after 
imatinib. Of patients who get resected, 48% to 91% have R0 
or R1 resections, with documented improvement in survival. 
However, these resections have been done in specialty centers 
with highly selected patients using an aggressive approach 
(Figure 2); 60% involved peritonectomy/omentectomy, 60% 
required multivisceral resections, and 40% involved resection 
of liver metastases.24,27,29,32–34
Two-thirds of patients with metastatic GIST develop liver 
metastases at some time during their course, and the liver can 
often be the only site of metastatic disease. Such liver lesions 
are often multifocal and may require multiple or repeated 
medical and surgical interventions to render the liver without 
evidence of disease, including radiofrequency ablation and 
hepatic artery embolization.35
One of the largest series of surgical outcomes using this 
approach was reported by Raut and colleagues at the Brigham 
and Women’s Hospital in Boston. These authors reported 
their surgical results in 69 consecutive patients in terms of the 
preoperative response (on imaging) to imatinib (Table 1), cat-
egorizing responses as “stable disease” (no progression of the 
index lesions by the time of operation), “limited progression” 
(progression of 1 target), or “generalized progression” 
(progression of more than 1 target lesion). R0 or R1 resections 
Tumor nodules
Bowel and 
mesentery
Figure 2 intraoperative photograph of advanced GiST after imatinib therapy showing 
multiple tumor nodules on the bowel and mesentery despite a good radiographic 
response. resection of this disease requires an aggressive approach, which frequently 
includes peritonectomy/omentectomy, multivisceral resections, and resection of liver 
(courtesy Dr C Corless).OncoTargets and Therapy 2009:2 157
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were accomplished in the majority of stable disease cases, 
whereas in almost half of generalized progression patients 
all gross disease could not resected. At 1 year the progres-
sion free and overall survival were high for stable disease 
patients, but all generalized disease had died of their tumors. 
The authors concluded that resection on imatinib is reasonable 
unless patients have generalized progression.32
Imatinib-resistant GIST: options
For patients progressing on imatinib, options include the 
multitarget TKI sunitinib (Sutent®; Pfizer), usually given 
orally at 37.5 mg/day. This drug primarily targets kit 
exon 9 mutants, forms of GIST that often do not respond 
to 400 mg/day imatinib.36 Studies of newer TKIs, such as 
dasatinib and nilotinib (which can act through signaling path-
ways other than c-KIT and PDGF-R),37 are currently ongoing, 
as are studies with IPI-504, a heatshock protein 90 inhibitor. 
Work in GIST cell lines suggests that treatment with 
dasatinib or IPI-504 may provide a therapeutic alternative 
for GIST patients whose tumors carry the imatinib-resistant 
PDGR-F(D842V) mutant isoform.38
RAD001, an mTOR inhibitor, is currently in trial given 
in combination with imatinib in imatinib-resistant GISTs. 
The use of imatinib combined with chemo agents can be 
considered, based on evidence from CML patients.3,39–41
GIST genotyping: current 
recommendations
For all patients with GIST, especially those who develop 
advanced and/or imatinib resistant disease, the questions 
of whether and when to genotype the tumor (ie, perform 
mutational analysis) usually arise. The most recent (2007) 
NCCN guidelines recommend genotyping “ALL high risk 
and malignant (ie, advanced) GISTs”.8
In fact, the vast majority of GIST tumors have a kit 
mutation, and most of these are at exon 11. Exon 11 mutations 
are usually associated with tumors that are located in the 
stomach, have a more favorable outcome, and initially 
respond to imatinib, although they may fail later. Fewer 
tumors have exon 9 mutations; these mutations are associated 
with nongastric sites, a less favorable prognosis, and respond 
less to imatinib at 400 mg/day – they may respond to 800 mg 
doses. Least favorable, and fortunately less common, are 
tumors with no kit mutation (“wild type”). These fail earlier 
and do not typically respond to TKIs. Pediatric GISTs are 
commonly wild type and this is reflected clinically by their 
aggressive morphology – these tumors are often multifocal, 
nodular, and node-positive. Specific gene mutations, such 
as codon 557–558 deletion and hTERT overexpression also 
mark high risk tumors.16,32
At our center, therefore, we do perform genotyping 
for specific indications where the information can be used 
clinically. We genotype all pediatric GISTs; while most are 
wild type and will do poorly on TKIs, a few have adult-type 
genotypes (exon 11 and 9 mutations) and TKIs may be 
indicated. The knowledge that a tumor expresses an exon 
9 mutation marks cases where 800 mg/day of imatinib should 
be tried. For patients who are either being considered for or 
are already failing sunitinib, some mutations, such as the 
novel kit exon 16 mutation L783V, predict clinical sunitinib 
resistance and mark patients who may not respond to this 
drug. Secondary mutations of the kit activation loop confer 
cross-resistance to both imatinib and sunitinib, and mark 
patients for whom TKIs may not be effective. Some imatinib 
resistant tumors express mutated PDGF-R and may be targets 
for PDGF-R inhibitors.4,41
Patient-focused perspectives:  
quality of life, patient satisfaction, 
and support
The advent of targeted therapy has converted high risk and 
metastatic GIST from a deadly disease to one where the chief 
issues are disease control, timing of therapies, and quality of 
life (QOL). Accordingly, support groups for patients facing 
therapy for GIST have appeared and have a very real role 
in advocacy for affected patients and their caregivers. Two 
of the largest include GIST Support International (www. 
gistsupport.org), a world wide organization of patients 
and caregivers which provides information and one-time 
grants for patient treatment, and Life Raft Group (www.
liferaftgroup.org), a 501c national group with local chapters, 
which provides information, support, and advocacy.
Table 1 Outcomes of resection in patients with advanced GiST 
on tyrosine kinase inhibitors (n = 69)
Stable 
disease
Limited 
progression
Generalized 
progression
r0–r1 78% 25% 7%
r2 4% 16% 43%
1-year PFS 80% 33% 0%
1-year OS 95% 86% 0%
Adapted with permission from raut CP, Posner M, Desai J, et al. Surgical management 
of advanced gastrointestinal stromal tumorsafter treatment with targeted systemic 
therapy using kinase inhibitors.  J Clin Oncol. 2006;24:2325–31.32 Copyright © 2006 
American Society of Clinical Oncology.
Abbreviations: r0–r1, complete resection of all microscopic or macroscopic 
disease, respectively; r2, gross residual disease left behind; PFS, progression-free 
survival; OS, overall survival.OncoTargets and Therapy 2009:2 158
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Because the health-related QOL and economic burden of 
GIST are timely from a payer, provider and patient perspective 
and may provide guidance for treatment decision making and 
reimbursement, it is not surprising that an extensive literature 
on these topics has appeared. Reddy and colleagues performed 
a systematic literature review of PubMed and 5 scientific 
meeting databases to identify and review 34 published 
studies and abstracts describing the epidemiologic, QOL 
and economic impact of GIST. Meta-analysis of these 
publications revealed that on the Functional Assessment 
of Chronic Therapy-fatigue (FACT-f) instrument, GIST 
patients scored 40.0 compared with 37.6 in anemic cancer 
patients (0 = worst; 52 = least fatigue). Reported total costs 
over 10 years for managing GIST patients with molecular 
targeted therapy averaged approximately £47,521 to £56,146 
per patient compared with £4,047 to £4,230 per patient with 
best supportive care. They concluded from their review that 
the health-related QOL burden of GIST is similar to that with 
other cancers, and the value of new therapies in GIST need 
to consider not only cost but also anticipated benefits and the 
unmet medical need in this condition.42
Summary: the place of surgery  
and targeted therapy  
in the treatment of GIST
GISTs, the most common sarcoma of the GI tract, have unique 
kinase mutations that serve as targets for medical therapy. 
Although an R0 surgical resection (microscopic negative 
specimen margins) remains the mainstay of treatment for 
these tumors, patients with resected GISTs have high relapse 
rates that can be reduced by 1 year of adjuvant imatinib. Data 
from studies supporting the use of imatinib in the adjuvant 
setting are still maturing, and the appropriate patient subsets 
and optimal duration of treatment are still unknown. For 
patients undergoing an R1 resection (tumor at 1 or more 
microscopic margins) options include either re-resection or 
imatinib, depending on the clinical setting.
Data clearly support the use of imatinib for patients with 
recurrent or unresectable GIST. In these patients the drug 
should be continued until progression, intolerance, or the 
patients are rendered resectable. Patients with advanced GIST 
who are successfully resected (R0 or R1) after imatinib treat-
ment should be placed back on imatinib post-operatively. For 
patients who progress on 400 mg imatinib, the dose can be 
increased to 800 mg/day. Patients who develop generalized 
progression (progression at 2 or more sites) even on this 
higher dose should move to other treatments, such as newer 
TKIs or other targeted approaches currently under study. 
Genotyping of the tumor should be considered in all pedi-
atric GISTs and high risk adult GISTs, especially if there 
is progression on imatinib. QOL and cost/benefit of new 
therapies are important issues for further study in patients 
with GIST.
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